Résumé
Objective To research the difference of medicines prices in the new round of centralized purchasing from 10 provinces,and provide references for further perfecting centralized medicines procurement of provinces in China.Methods Based on the 2015 national sample hospital medicines procurement ranking list and the new round centralized procurement of every province,15 kinds of medicines are selected.By comparative studying,the difference of 15 medicines price among 10 provinces is analyzed.And the difference of prices between the domestic medicines and imported medicines in reference to WHO/HAl drug price standard survey method,the prices of medicines in each province and the international reference prices are analyzed.Results The medicine prices are different in different provinces.The medicines prices of Fujian Province are obviously lower than other provinces.The prices of a few imported medicines are obviously higher than those of domestic ones.Median prices ratios of some medicines exceed the reasonable range.Conclusion It is suggested that every province should refer to the useful experience of Fujian Province in medicines centralized procurement,to improve their centralized procurement plans.Every province should grant equal bids for imported patents,domestic generic drugs and original medicines,to make them have consistency bidding.The international reference price is incorporated into the price limit reference system,to make more reasonable price limit standard.
Résumé
Objective:This paper aims to analyze the monitoring model of Canadian drug price monitoring mod-el based on the international reference price, and make reference for China. Methods: Through policy analysis and literature research, the system combs the specific Canadian practices of using the international reference prices for the drug price monitoring. Results:For the introduction of new drug prices, Canada uses the international median price comparison test, the highest international price comparison test, the treatment category comparison test and the inter-national treatment category comparison test. For the listed drugs, Canada calculates the international price ratio, and then carries out bilateral comparisons and multilateral comparisons to monitor the prices of drugs already on the mar-ket. At present, Canada has achieved effective monitoring of drug prices, that is to say, the introduction of new drug prices complies with the《Excessive Price Guide》;the patented drugs prices are lower than the designed international price;the price difference between the generic drug and the international level has gradually reduced. Conclusions:The Canadian experience is worth learning, and China should add legislative about drug price monitoring, learn from this experience to identify and monitor the varieties and establish the price monitoring and early warning mechanism with the international reference price as the warning indicator.